2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $887M | $1.1B | $1.1B | $1.1B | $1.2B |
Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
Gross Profit | $887M | $1.1B | $1.1B | $1.1B | $1.2B |
Gross Profit % | 100% | 100% | 100% | 100% | 100% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | -$176M | $144M | -$402K | -$39M | -$3.9M |
Dep. & Amort. | $21M | $37M | $38M | $26M | $0 |
Def. Tax | -$21M | $1.3M | -$6.6M | -$1.8M | $0 |
Stock Comp. | $3.8M | $4.4M | $4.8M | $5.2M | -$1.3M |
Chg. in WC | $61M | $13M | -$124M | -$82M | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $216M | $144M | $30M | $66M | $55M |
ST Investments | $2.8B | $4.1B | $3.7B | $236M | $255M |
Cash & ST Inv. | $3B | $4.2B | $3.7B | $66M | $310M |
Receivables | $0 | $0 | $0 | $0 | $229M |
Inventory | -$774M | -$610M | $0 | $0 | $0 |
PRA reported its fifth consecutive quarter of improved operating earnings, with significant progress in the medical professional liability business, part of the Specialty P&C segment.
Renewal premium increases in the Specialty P&C segment were 10% and 8% in Q4, contributing to a cumulative 70% increase since 2018, while retention rates remained strong at 83%.
Workers' Compensation segment saw a slight increase in net written premiums for the year, with a full-year combined ratio of 114% and improvements in loss ratios due to underwriting and pricing actions.
Net investment income rose 12% for the year, with new purchase yields at 5.8%, and book value per share increased to $23.49, driven by earnings and gains in accumulated other comprehensive income.
The company remains focused on disciplined underwriting, leveraging AI tools, and maintaining profitability over growth, with expectations for continued progress in 2025 despite competitive market conditions.